PriceTargets.com logo

Eloxx Pharmaceuticals - ELOX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.33
  • Forecasted Upside: 194.19%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 2 Strong Buy Ratings
$13.03 As of 10/16/2026 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for ELOX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eloxx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELOX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELOX

Analyst Price Target is $38.33
▲ +194.19% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Eloxx Pharmaceuticals in the last 3 months. The average price target is $38.33, with a high forecast of $43.00 and a low forecast of $32.00. The average price target represents a 194.19% upside from the last price of $13.03.

This chart shows the closing price for ELOX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Eloxx Pharmaceuticals. This rating has held steady since August 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2026
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2026
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/19/2026

Latest Recommendations

  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/15/2026Cantor FitzgeraldInitiated CoverageOverweight
9/18/2026Leerink PartnersSet TargetOutperform$32.00
9/18/2026Leerink PartnersUpgradeStrong-Buy$32.00
8/24/2026GuggenheimReiterated RatingBuy ➝ Buy$43.00
8/20/2026Lucid Cap MktsUpgradeStrong-Buy
8/14/2026Weiss RatingsInitiated CoverageSell (D)
7/22/2026Lifesci CapitalInitiated CoverageOutperform$40.00
7/20/2026GuggenheimInitiated CoverageBuy$43.00
7/20/2026GuggenheimInitiated CoverageBuy$43.00
(Data available from 10/19/2021 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2026

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Eloxx Pharmaceuticals logo
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
Read More

Today's Range

Now: $13.03
Low: $12.85
High: $14.15

50 Day Range

MA: $16.32
Low: $12.21
High: $20.98

52 Week Range

Now: $13.03
Low: $8.20
High: $23.40

Volume

66,492 shs

Average Volume

23,764 shs

Market Capitalization

$52.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Eloxx Pharmaceuticals?

The following equities research analysts have issued stock ratings on Eloxx Pharmaceuticals in the last year: Cantor Fitzgerald, Guggenheim, Leerink Partners, Lifesci Capital, Lucid Cap Mkts, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ELOX.

What is the current price target for Eloxx Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Eloxx Pharmaceuticals in the last year. Their average twelve-month price target is $38.33, suggesting a possible upside of 194.2%. Guggenheim has the highest price target set, predicting ELOX will reach $43.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $32.00 for Eloxx Pharmaceuticals in the next year.
View the latest price targets for ELOX.

What is the current consensus analyst rating for Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals currently has 1 sell rating, 3 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELOX will outperform the market and that investors should add to their positions of Eloxx Pharmaceuticals.
View the latest ratings for ELOX.

What other companies compete with Eloxx Pharmaceuticals?

Other companies that are similar to Eloxx Pharmaceuticals include Alpha Cognition, Zentalis Pharmaceuticals, Journey Medical, Jyong Biotech and Silverback Therapeutics. Learn More about companies similar to Eloxx Pharmaceuticals.

How do I contact Eloxx Pharmaceuticals' investor relations team?

Eloxx Pharmaceuticals' physical mailing address is P.O. BOX 274, ARLINGTON, MA 02476. The company's listed phone number is 781-577-5300 and its investor relations email address is [email protected]. The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com. Learn More about contacing Eloxx Pharmaceuticals investor relations.